New method to target cancer growth by regulating a specific protein
Development of an Anti-Cancer Approach Through a Novel Pathway of Translational Regulation
This study is exploring a new way to slow down cancer growth by targeting a protein called STAT3 that can be too active in tumors, and if successful, it could help patients by reducing the growth of cancer cells.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Tech University Health Scis Center NIH-funded |
| Lab location | 1 site (Lubbock, United States) |
| Project ID | NIH-10727837 on NIH RePORTER |
What this research studies
This research investigates a novel approach to inhibit cancer growth by targeting the STAT3 protein, which is often overactive in many tumors. The study focuses on a newly discovered pathway that controls the synthesis of proteins, aiming to reduce the expression of STAT3 during its production. By manipulating this pathway, the researchers hope to decrease abnormal cell growth and tumor progression. Patients may benefit from this innovative strategy if it proves effective in controlling cancer cell proliferation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cancers that exhibit high levels of STAT3 activity.
Not a fit: Patients with cancers that do not involve STAT3 dysregulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that more effectively inhibit cancer growth by targeting the STAT3 protein.
How similar studies have performed: While targeting STAT3 has been explored, this specific approach using the RAPP pathway is novel and has not been tested before.
Where this research is happening
Lubbock, United States
- Texas Tech University Health Scis Center — Lubbock, United States (Active)
Researchers
- Principal investigator: Karamyshev, Andrey L — Texas Tech University Health Scis Center
- Study coordinator: Karamyshev, Andrey L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.